AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21112400 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact V2rf2
Number of subjects: 0
Study 21112400 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted deletion of V2rf2
Number of subjects: 0
Study 21112400 — intervention group
Group type: COMPARATOR
Intervention: Postnatal wild-type mice
Number of subjects: 0
Study 18325601 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine 0.25% (Group L)
Number of subjects: 75
Study 18325601 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25% plus magnesium sulphate 2mg/kg (Group M)
Number of subjects: 75
Study 18325601 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (Group S)
Number of subjects: 75
Study 18325601 — intervention group
Group type: COMPARATOR
Intervention: Control (Group S)
Number of subjects: 75
Study 16929430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless Harris-Galante II cup (experimental group)
Number of subjects: 52
Study 16929430 — intervention group
Group type: COMPARATOR
Intervention: Cemented Spectron stem (control group)
Number of subjects: 52
Study 14618047 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic conversion strategy (n = 27)
Number of subjects: 50
Study 14618047 — intervention group
Group type: COMPARATOR
Intervention: Rate-control strategy (n = 23)
Number of subjects: 50
Study 14618047 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic conversion strategy
Number of subjects: 50
Study 14618047 — intervention group
Group type: COMPARATOR
Intervention: Rate-control strategy
Number of subjects: 50
Study 10918423 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-rHuMGDF (1.0, 2.5, 5.0, 7.5, or 10.0 microg/kg/day)
Number of subjects: 47
Study 10918423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 8967471 — intervention group
Group type: EXPERIMENTAL
Intervention: acipimox
Number of subjects: 34
Study 8967471 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study 1729559 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthesia with EMLA cream applied on one side of the scrotum.
Number of subjects: 42
Study 1729559 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthesia with EMLA cream applied on one side of the scrotum before bilateral mepivacaine infiltration.
Number of subjects: 42
Study 1729559 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration anesthesia with mepivacaine on the contralateral side (first trial).
Number of subjects: 42
Study 6710300 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 per cent chlorhexidine gluconate spray
Number of subjects: 737
Study 6710300 — intervention group
Group type: COMPARATOR
Intervention: povidone‐iodine scrub
Number of subjects: 737
Study 3088636 — intervention group
Group type: EXPERIMENTAL
Intervention: Binedaline (50 mg)
Number of subjects: 0
Study 3088636 — intervention group
Group type: EXPERIMENTAL
Intervention: Binedaline (100 mg)
Number of subjects: 0
Study 3088636 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (75 mg)
Number of subjects: 0
Study 3088636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29300925 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (0.8 mg/kg/dose)
Number of subjects: 11
Study 29300925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 27454114 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity program
Number of subjects: 25
Study 27454114 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 25
Study 24728287 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthotopic transplantation (OT)
Number of subjects: 334
Study 24728287 — intervention group
Group type: COMPARATOR
Intervention: Heterotopic transplantation (HT)
Number of subjects: 334
Study 24131882 — intervention group
Group type: EXPERIMENTAL
Intervention: Discretionary time spent with peers
Number of subjects: 25
Study 24131882 — intervention group
Group type: EXPERIMENTAL
Intervention: Discretionary time spent with parents
Number of subjects: 25
Study 24131882 — intervention group
Group type: EXPERIMENTAL
Intervention: Discretionary time social context
Number of subjects: 25
Study 24131882 — intervention group
Group type: EXPERIMENTAL
Intervention: Eighth graders
Number of subjects: 25
Study 19927151 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (20 mg day(-1))
Number of subjects: 50
Study 19927151 — intervention group
Group type: COMPARATOR
Intervention: Candesartan (8 mg day(-1))
Number of subjects: 50
Study 19055225 — intervention group
Group type: COMPARATOR
Intervention: Acellular dermal matrix
Number of subjects: 0
Study 19055225 — intervention group
Group type: COMPARATOR
Intervention: New surgical approach with acellular dermal matrix
Number of subjects: 0
Study 19055225 — intervention group
Group type: COMPARATOR
Intervention: Acellular dermal matrix alone
Number of subjects: 0
Study 16604818 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta‐1b‐G (glucose formulation)
Number of subjects: 303
Study 16604818 — intervention group
Group type: COMPARATOR
Intervention: IFNbeta‐1b‐M (refrigeration-free formulation)
Number of subjects: 303
Study 14705469 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping instruction
Number of subjects: 66
Study 14705469 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping instruction (coping alone or coping plus information)
Number of subjects: 66
Study 14705469 — intervention group
Group type: COMPARATOR
Intervention: No coping instruction (control group)
Number of subjects: 66
Study 10663062 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon-Plasma-Coagulation tonsillectomy (TE-APC)
Number of subjects: 133
Study 10663062 — intervention group
Group type: COMPARATOR
Intervention: Traditional blunt dissection tonsillectomy (TE-trad)
Number of subjects: 133
Study 8851595 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosing (CD) vancomycin therapy (1 g every 12 h)
Number of subjects: 10
Study 8851595 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-infusion (CI) vancomycin therapy (500 mg loading dose followed by 2 g infused over 24 h)
Number of subjects: 10
Study 1496949 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatotropin recombinant DNA (24 IU/m2 of body surface area) subcutaneously administered in six injections per week for 2 years
Number of subjects: 52
Study 1496949 — intervention group
Group type: COMPARATOR
Intervention: Somatotropin recombinant DNA (24 IU/m2 of body surface area) subcutaneously administered in three injections per week for 2 years
Number of subjects: 52
Study 6149737 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) benztropine mesylate (2 mg)
Number of subjects: 36
Study 6149737 — intervention group
Group type: COMPARATOR
Intervention: Oral benztropine mesylate (2 mg three times a day)
Number of subjects: 36
Study 6149737 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptic withdrawal (four weeks of dose tapering and six weeks of placebo treatment)
Number of subjects: 36
Study 29927751 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-motor exercise program
Number of subjects: 28
Study 29927751 — intervention group
Group type: COMPARATOR
Intervention: Monitoring (control group)
Number of subjects: 28
Study 30403937 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug regimen (ivermectin + diethylcarbamazine + albendazole)
Number of subjects: 182
Study 30403937 — intervention group
Group type: COMPARATOR
Intervention: Two-drug regimen (diethylcarbamazine + albendazole) - single dose
Number of subjects: 182
Study 30403937 — intervention group
Group type: COMPARATOR
Intervention: Two-drug regimen (diethylcarbamazine + albendazole) - administered once a year for 3 years
Number of subjects: 182
Study 30403937 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug regimen
Number of subjects: 182
Study 26718094 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive-Behavioral Treatment (GCBT)
Number of subjects: 196
Study 26718094 — intervention group
Group type: COMPARATOR
Intervention: Group Supportive Counseling Approach (GPCT)
Number of subjects: 196
Study 25323538 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower seed oil (SSO) applied daily during the first 10 postnatal days
Number of subjects: 22
Study 25323538 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) with no intervention
Number of subjects: 22
Study 22984233 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manual treatment (OMT)
Number of subjects: 70
Study 22984233 — intervention group
Group type: COMPARATOR
Intervention: Sham OMT
Number of subjects: 70
Study 20733134 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midostaurin at 50 or 100 mg twice daily
Number of subjects: 95
Study 20733134 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midostaurin at 100 mg twice daily
Number of subjects: 95
Study 20733134 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midostaurin at 50 mg twice daily
Number of subjects: 95
Study 19050548 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15797173 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard instructions
Number of subjects: 60
Study 15797173 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to simulate pain-related memory deficit
Number of subjects: 60
Study 15797173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-induced pain
Number of subjects: 60
Study 11753159 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 10 mg/kg, 8 hourly for 7 days
Number of subjects: 20
Study 11753159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9848502 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soy protein containing 1.39 mg isoflavones/g protein (ISP56)
Number of subjects: 66
Study 9848502 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soy protein containing 2.25 mg isoflavones/g protein (ISP90)
Number of subjects: 66
Study 9848502 — intervention group
Group type: COMPARATOR
Intervention: Casein and nonfat dry milk (CNFDM)
Number of subjects: 66
Study 8019165 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of oxybutynin
Number of subjects: 36
Study 2754021 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine treatment 10 mg b.i.d. for 8 weeks
Number of subjects: 11
Study 2754021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 20121 — intervention group
Group type: EXPERIMENTAL
Intervention: Air injection technique
Number of subjects: 11
Study 31129587 — intervention group
Group type: EXPERIMENTAL
Intervention: S100B biomonitoring group
Number of subjects: 0
Study 31129587 — intervention group
Group type: COMPARATOR
Intervention: Conventional management control group
Number of subjects: 0
Study 29525602 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg aflibercept
Number of subjects: 436
Study 29525602 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg bevacizumab
Number of subjects: 436
Study 29525602 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 436
Study 29525602 — intervention group
Group type: COMPARATOR
Intervention: aflibercept
Number of subjects: 436
Study 29525602 — intervention group
Group type: COMPARATOR
Intervention: bevacizumab
Number of subjects: 436
Study 26404015 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress myocardial perfusion single photon emission computed tomography (SPECT)
Number of subjects: 299
Study 26404015 — intervention group
Group type: EXPERIMENTAL
Intervention: High end-systolic volume (ESV) and high summed stress score (SSS)
Number of subjects: 299
Study 26404015 — intervention group
Group type: EXPERIMENTAL
Intervention: Low estimated glomerular filtration rate (eGFR) and high summed difference score (SDS)
Number of subjects: 299
Study 25173954 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (1 mA, 20 min)
Number of subjects: 28
Study 25173954 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 28
Study 22169831 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (3 J) and exercises
Number of subjects: 40
Study 22169831 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser and exercises
Number of subjects: 40
Study 19605849 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine (25 mg/m² for 5 days intravenously, every 28 days, for 6 courses)
Number of subjects: 193
Study 19605849 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil (0.4 mg/kg body weight with an increase to 0.8 mg/kg, every 15 days, for 12 months)
Number of subjects: 193
Study 17261329 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0
Study 17261329 — intervention group
Group type: COMPARATOR
Intervention: Untreated OSA
Number of subjects: 0
Study 14872250 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 W exercise intensity
Number of subjects: 5
Study 14872250 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 W exercise intensity
Number of subjects: 5
Study 14872250 — intervention group
Group type: EXPERIMENTAL
Intervention: 175 W exercise intensity
Number of subjects: 5
Study 14872250 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 W exercise intensity
Number of subjects: 5
Study 11669361 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy-based cholesterol management program
Number of subjects: 300
Study 11669361 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study 8980759 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg orally every 12 h for 45 days + Gentamicin 240 mg intramuscularly once daily for 7 days
Number of subjects: 52
Study 8980759 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline at the same dosage for 30 days + Gentamicin 240 mg intramuscularly once daily for 7 days
Number of subjects: 52
Study 8980759 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cohorts (Doxycycline and Gentamicin)
Number of subjects: 52
Study 8945276 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile cartridge‐needle units (Carpuject)
Number of subjects: 6
Study 8945276 — intervention group
Group type: COMPARATOR
Intervention: Conventional disposable syringes with multiple‐ and single‐dose vials
Number of subjects: 6
Study 2886245 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg famotidine
Number of subjects: 10
Study 2886245 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg famotidine
Number of subjects: 10
Study 2886245 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine
Number of subjects: 10
Study 2886245 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine at 9 PM only
Number of subjects: 10
Study 29775687 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (Sal)
Number of subjects: 45
Study 29775687 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (FF)
Number of subjects: 45
Study 29775687 — intervention group
Group type: EXPERIMENTAL
Intervention: LABA (Salmeterol or Formoterol)
Number of subjects: 45
Study 28809789 — intervention group
Group type: EXPERIMENTAL
Intervention: G-Breakfast
Number of subjects: 0
Study 28809789 — intervention group
Group type: COMPARATOR
Intervention: C-Breakfast
Number of subjects: 0
Study 24681850 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) with adaptive statistical iterative reconstruction (ASIR) blending ratios (0%, 30%, 50%, and 70%)
Number of subjects: 79
Study 24681850 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose computed tomography (SDCT)
Number of subjects: 79
Study 23596142 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg)
Number of subjects: 40
Study 23596142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20921462 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab 6.0 mg/kg plus FOLFIRI
Number of subjects: 1186
Study 20921462 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI alone
Number of subjects: 1186
Study 18826749 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost (a.m. dosing)
Number of subjects: 51
Study 18826749 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost (a.m. dosing)
Number of subjects: 51
Study 18826749 — intervention group
Group type: COMPARATOR
Intervention: Travoprost (evening dosing)
Number of subjects: 51
Study 18826749 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost (evening dosing)
Number of subjects: 51
Study 18826749 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 51
Study 16980830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (life skills intervention)
Number of subjects: 116
Study 14585918 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valdecoxib 20 mg once daily
Number of subjects: 0
Study 14585918 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg twice daily
Number of subjects: 0
Study 10805622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (AHA pamphlet + pharmacologic information + standardized counseling)
Number of subjects: 152
Study 10805622 — intervention group
Group type: COMPARATOR
Intervention: Control group (AHA pamphlet only)
Number of subjects: 152
Study 8614068 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential gradient intermittent pneumatic compression (SGIPC)
Number of subjects: 0
Study 8614068 — intervention group
Group type: COMPARATOR
Intervention: Control (phase I)
Number of subjects: 0
Study 8184809 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril therapy
Number of subjects: 52
Study 8184809 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 52
Study 3115668 — intervention group
Group type: EXPERIMENTAL
Intervention: PETCO2 elevated to 50 mmHg during the test period
Number of subjects: 5
Study 3115668 — intervention group
Group type: COMPARATOR
Intervention: PETCO2 kept at 40 mmHg during the test period
Number of subjects: 5
Study 3115668 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in PETCO2 from 40 to 50 mmHg
Number of subjects: 5
Study 30509397 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT)
Number of subjects: 35
Study 30509397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 28057075 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory training plus metacognitive skills training (COMP-MST)
Number of subjects: 90
Study 28057075 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory training only (COMP)
Number of subjects: 90
Study 28057075 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 90
Study 24476829 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive self-management (CSM) intervention
Number of subjects: 0
Study 24476829 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 0
Study 22321131 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm reduction focused school drug education program (10 lessons in year eight and 8 lessons in year nine)
Number of subjects: 1746
Study 22321131 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving the normal drug education provided in their schools
Number of subjects: 1746
Study 21059712 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapor rub (VR)
Number of subjects: 138
Study 21059712 — intervention group
Group type: EXPERIMENTAL
Intervention: Petrolatum
Number of subjects: 138
Study 21059712 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 138
Study 17464140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hemodialysis (IHD)
Number of subjects: 0
Study 17464140 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow extended daily dialysis (SLEDD)
Number of subjects: 0
Study 17464140 — intervention group
Group type: COMPARATOR
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 0
Study 15865489 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga group (169 women)
Number of subjects: 335
Study 15865489 — intervention group
Group type: COMPARATOR
Intervention: Control group (166 women)
Number of subjects: 335
Study 12200949 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 75 micrograms with prilocaine 75 mg
Number of subjects: 40
Study 12200949 — intervention group
Group type: COMPARATOR
Intervention: Control group (prilocaine 75 mg alone)
Number of subjects: 40
Study 9683043 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure (HBP) method
Number of subjects: 189
Study 9683043 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory Blood Pressure (ABP) method
Number of subjects: 189
Study 7508826 — intervention group
Group type: EXPERIMENTAL
Intervention: c7E3 Fab
Number of subjects: 60
Study 7508826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3397523 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofepramine 70 mg
Number of subjects: 10
Study 3397523 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofepramine 140 mg
Number of subjects: 10
Study 3397523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine 100 mg
Number of subjects: 10
Study 3397523 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 50 mg
Number of subjects: 10
Study 3397523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31785169 — intervention group
Group type: EXPERIMENTAL
Intervention: Daylight photodynamic therapy (DPDT)
Number of subjects: 24
Study 31785169 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy (control)
Number of subjects: 24
Study 29462482 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant S-1 therapy
Number of subjects: 440
Study 29462482 — intervention group
Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 440
Study 28169983 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative inspiratory muscle training (IMT) using a threshold load inspiratory muscle trainer
Number of subjects: 40
Study 28169983 — intervention group
Group type: COMPARATOR
Intervention: Usual care (preoperative education and postoperative routine physical therapy)
Number of subjects: 40
Study 26314389 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (swallowed topical corticosteroids)
Number of subjects: 69
Study 26314389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 23127920 — intervention group
Group type: EXPERIMENTAL
Intervention: CIDR-G of first use (new devices)
Number of subjects: 319